Phase II randomized, double-blind, placebo-controlled study of CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.

Trial Profile

Phase II randomized, double-blind, placebo-controlled study of CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Eflornithine (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 New trial record
    • 17 Jul 2017 According to a Cancer Prevention Pharmaceuticals media release, Vanderbilt University Medical Center is a center for this trial.
    • 17 Jul 2017 According to a Cancer Prevention Pharmaceuticals media release, this trial is funded by the National Cancer Institute (NCI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top